October 2019 Br J Cardiol 2019;26(4)
Richard Armstrong, Amar Puttana, BJC Staff
Abstract
ESC President, Professor Barbara Casadei
Heart failure highlights
PARAGON-HF fails primary end point but benefits for some
Heart failure was a key theme of this year’s congress, accounting for more than 1,000 presentations. In the first hotline session of the Congress, the keenly awaited results from PARAGON-HF (Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction) were presented.1
Up to 64 million people worldwide have heart failure, and that number is rising as the population ages. Evidence-based treatment has focused on about half of these patients who have heart failure with reduced ejection fraction (<
|
Full text